Sibrotuzumab

DB06474InvestigationalProtein Based Therapies

Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.

Mechanism: Human FAP is unique in its selective expression by tumor stromal fibroblasts in epithelial carcinomas, but not by epithelial carcinoma cells, normal fibroblasts, or other normal tissues. Therefore, FAP is an attractive target for the study of tumor stromal cell biology and provides valuable insights into the roles of the tumor microenvironment. Sibrotuzumab is a humanized monoclonal antibody designed to attack the cell-surface antigen FAP.
Curator reviewed
Primary indication: Investigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer.Curator reviewed
Code names: BIBH 1

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

2Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Sibrotuzumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.